Fireman B.V. Down 7.10% To $1.57 After Earnings

reported that it broke-even during the quarter.



The stock is down 7.10% to $1.57 after the report.

The firm's lower revenue growth to earnings signals that the firm has been able to reduce costs and improve its profit margin overall.

The average recommendation from Wall Street analysts was a Strong Buy which may get revised based on this new data.

InvestorsObserver gives the stock a Bullish Sentiment score at the moment based on recent trading.

Fireman B.V. has performed a little below average during the past few months. Before the report, Fireman B.V. received a Long-Term Technical Rank by InvestorsObserver of 44, putting it in the bottom half of stocks. The firm set a 52-week low on November 10, 2023 at $1.14 and set a 52-week high on April 5, 2023 at $7.25.

InflaRx NV is a clinical-stage biopharmaceutical company focused on applying proprietary anti-C5a/C5aR technology to discover and develop first-in-class, potent and specific inhibitors of the complement activation factor known as C5a and its receptor known as C5aR. C5a is an inflammatory mediator involved in the progression of a wide variety of autoimmune and other inflammatory diseases. Its lead product candidate, vilobelimab, is a novel intravenously delivered first-in-class anti-C5a monoclonal antibody that selectively binds to free C5a and has demonstrated disease-modifying clinical activity and tolerability in multiple clinical settings.